Share on StockTwits

Horizon Pharma (NASDAQ:HZNP) has been given an average rating of “Hold” by the eight analysts that are currently covering the stock, American Banking News.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.14.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Horizon Pharma from an “outperform” rating to a “neutral” rating in a research note on Thursday, July 31st. They now have a $11.00 price target on the stock. Separately, analysts at Piper Jaffray downgraded shares of Horizon Pharma from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $9.00 price target on the stock, down previously from $22.00. Finally, analysts at Piper Jaffray initiated coverage on shares of Horizon Pharma in a research note on Monday, July 7th. They set an “overweight” rating on the stock.

Shares of Horizon Pharma (NASDAQ:HZNP) traded up 2.79% on Tuesday, hitting $9.9601. The stock had a trading volume of 128,369 shares. Horizon Pharma has a 1-year low of $2.11 and a 1-year high of $18.30. The stock’s 50-day moving average is $12.26 and its 200-day moving average is $13.26. The company’s market cap is $744.7 million.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.11. The company had revenue of $66.10 million for the quarter, compared to the consensus estimate of $58.35 million. The company’s quarterly revenue was up 495.5% on a year-over-year basis. Analysts expect that Horizon Pharma will post $0.69 EPS for the current fiscal year.

Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.